Immucor pays $25 million for Gamma Biologicals
This article was originally published in Clinica
Immucor will become the leading supplier of blood serology reagents and systems in the US and Canada following the acquisition of Gamma Biologicals, in a deal worth around $25 million. The transaction consists of a cash tender offer at $4.50 per share. On completion of the deal, expected in around five weeks, Gamma will operate as a wholly-owned subsidiary of Immucor.